Susceptibility of clinical Mycobacterium tuberculosis isolates to a potentially less toxic derivate of linezolid, PNU-100480

J W C Alffenaar; T van der Laan; S Simons; T S van der Werf; P J van de Kasteele; H de Neeling; D van Soolingen

doi:10.1128/AAC.01297-10

Susceptibility of clinical Mycobacterium tuberculosis isolates to a potentially less toxic derivate of linezolid, PNU-100480

Antimicrob Agents Chemother. 2011 Mar;55(3):1287-9. doi: 10.1128/AAC.01297-10. Epub 2011 Jan 3.

Authors

J W C Alffenaar¹, T van der Laan, S Simons, T S van der Werf, P J van de Kasteele, H de Neeling, D van Soolingen

Affiliation

¹ Department of Hospital and Clinical Pharmacy, University Medical Center Groningen, University of Groningen, P.O. Box 30.001, 9700 RB Groningen, Netherlands. j.w.c.alffenaar@apoth.umcg.nl

Abstract

Susceptibility of clinical Mycobacterium tuberculosis isolates to PNU-100480 and linezolid was evaluated by the MGIT 960 system. The isolates had various susceptibilities to isoniazid (INH), rifampin, ethambutol, and streptomycin. The mean MIC for PNU-100480 was 3.2 times lower than that for linezolid. Therefore, PNU-100480 is a promising candidate to be developed further as an adjunct in the treatment of multidrug- and extensively drug-resistant tuberculosis (MDR/XDR-TB).

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Acetamides / chemistry*
Antitubercular Agents / adverse effects
Antitubercular Agents / pharmacology*
Ethambutol / pharmacology
Isoniazid / pharmacology
Linezolid
Microbial Sensitivity Tests
Mycobacterium tuberculosis / drug effects*
Oxazolidinones / adverse effects
Oxazolidinones / chemistry*
Oxazolidinones / pharmacology*
Rifampin / pharmacology
Streptomycin / pharmacology
Tuberculosis, Multidrug-Resistant

Substances

Acetamides
Antitubercular Agents
Oxazolidinones
PNU-100480
Ethambutol
Linezolid
Isoniazid
Rifampin
Streptomycin